A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone.
A retrospective study was performed on the cost-effectiveness of treatment for advanced prostate cancer metastatic to bone. Patients (n = 29) recruited into the trans Canada trial at the Cross Cancer Institute, Edmonton and randomized to treatment with Metastron (strontium-89 chloride) (n = 14) or placebo (n = 15) after local field irradiation therapy for pain palliation were studied over their entire survival time. Estimates were made of the direct costs of treatment, i.e. drugs (analgesics and hormonal agents) and external radiotherapy, and the indirect costs (investigations, outpatient visits and inpatient days, either total or for tertiary care) based on records from the referring hospital, the cancer clinic and any hospitals to which the patients may subsequently have been referred. Meaningful differences were apparent between the two groups in direct costs with the group receiving Metastron showing a reduction over the entire survival time of Can$ 1,720/person compared with placebo; it should be noted that in this analysis neither the costs of the Metastron, nor of the initial radiotherapy, have been included. The Metastron group also showed a reduction in costs of hospitalization for tertiary care of Can$ 5,696/person, though the total cost of hospitalization was similar in the two groups. These results suggest that treatment with Metastron can bring about reductions in management costs for patients with advanced prostate cancer and, coupled with the findings of the Trans Canada trial on the improvement in quality of life for patients given Metastron, they add financial support to the clinical rationale for the use of Metastron for the palliative treatment of patients with bone metastases resulting from prostate cancer.
McEwan
A J
AJ
Cross Cancer Institute, Edmonton, Alta., Canada.
Amyotte
G A
GA
McGowan
D G
DG
MacGillivray
J A
JA
Porter
A T
AT
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D003362:Cost-Benefit Analysis; D017721:Hospital Costs; D006801:Humans; D008297:Male; D010166:Palliative Care / Q000191:economics*; D011471:Prostatic Neoplasms / Q000473:pathology*; D012189:Retrospective Studies; D013324:Strontium / Q000627:therapeutic use*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013326:Strontium Radioisotopes; C025700:strontium chloride; D013324:Strontium